# Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases

> **NCT03122431** · PHASE4 · COMPLETED · sponsor: **University of Sao Paulo General Hospital** · enrollment: 93 (actual)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)
- Juvenile SLE
- Cutaneous Lupus

## Interventions

- **DRUG:** Thalidomide
- **DRUG:** Hydroxychloroquine reduced
- **DRUG:** standard dose of HCQ

## Key facts

- **NCT ID:** NCT03122431
- **Lead sponsor:** University of Sao Paulo General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-05
- **Primary completion:** 2020-12-30
- **Final completion:** 2021-03-30
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2021-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03122431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03122431, "Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03122431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*